Reaction
Gastrointestinal Stoma Complication reporting signals
As of the last recalculation, Gastrointestinal Stoma Complication appears in 1,541 FAERS reports alongside 36 co-occurring drug terms. The strongest observed disproportionality signal is TEDUGLUTIDE (PRR 213.2).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Teduglutide | 187 | 213.2 | 216.2 |
| Diphenoxylate Hydrochloride And Atropine Sulfate | 33 | 33.2 | 33.3 |
| Dimenhydrinate | 23 | 29.6 | 29.6 |
| Loperamide Hydrochloride And Dimethicone | 48 | 20.8 | 20.9 |
| Loperamide Hydrochloride | 59 | 18.5 | 18.5 |
| Loperamide Hydrochloride Oral | 12 | 16.0 | 16.0 |
| Cholestyramine | 14 | 15.8 | 15.8 |
| Leucovorin Calcium | 22 | 15.8 | 15.8 |
| Octreotide Acetate | 33 | 14.8 | 14.9 |
| Loperamide Hcl | 14 | 14.8 | 14.8 |
| Vedolizumab | 84 | 13.9 | 13.9 |
| Hyoscyamine Sulfate | 9 | 13.3 | 13.3 |
| Azathioprine | 81 | 13.1 | 13.1 |
| Fluorouracil Cream, 0.5% | 59 | 10.8 | 10.8 |
| Fluorouracil | 59 | 10.7 | 10.7 |
| Oxaliplatin | 55 | 10.3 | 10.4 |
| Mercaptopurine | 13 | 10.2 | 10.2 |
| Trifluridine And Tipiracil | 8 | 10.1 | 10.1 |
| Infliximab-Dyyb | 21 | 9.8 | 9.8 |
| Adalimumab | 382 | 9.4 | 9.4 |
| Insulin Glulisine | 7 | 9.3 | 9.3 |
| Rifampin | 10 | 9.3 | 9.3 |
| Infliximab | 127 | 8.5 | 8.5 |
| Cetuximab | 19 | 8.3 | 8.3 |
| Niraparib | 13 | 8.0 | 8.0 |
| Capecitabine | 51 | 7.7 | 7.8 |
| Rucaparib | 5 | 7.7 | 7.7 |
| Irinotecan Hydrochloride | 7 | 7.4 | 7.4 |
| Panitumumab | 8 | 6.9 | 6.9 |
| Ustekinumab | 50 | 6.8 | 6.8 |
| Carbidopa And Levodopa | 22 | 6.3 | 6.3 |
| Rasagiline Mesylate | 5 | 6.1 | 6.1 |
| Bevacizumab | 53 | 6.0 | 6.0 |
| Daptomycin | 4 | 5.9 | 5.9 |
| Rotigotine | 6 | 5.6 | 5.6 |
| Risankizumab-Rzaa | 30 | 5.0 | 5.0 |